The Triple Threat of the Covid-19 Pandemic- (White, Yellow and Green Fungus)

International Journal of Medical Science
© 2021 by SSRG - IJMS Journal
Volume 8 Issue 8
Year of Publication : 2021
Authors : Raghavendra Rao M. V, Mubasheer Ali, Vijay Kumar Chennamchetty, Dilip Mathai, Tina Presilla, Yogendra Kumar Verma, Vishnu Rao.P, Mahendra Kumar Verma, Srinivasa Rao.D
How to Cite?

Raghavendra Rao M. V, Mubasheer Ali, Vijay Kumar Chennamchetty, Dilip Mathai, Tina Presilla, Yogendra Kumar Verma, Vishnu Rao.P, Mahendra Kumar Verma, Srinivasa Rao.D, "The Triple Threat of the Covid-19 Pandemic- (White, Yellow and Green Fungus)," SSRG International Journal of Medical Science, vol. 8,  no. 8, pp. 8-14, 2021. Crossref,


India has to prevent three deadly fungal infections Black fungus, White fungus and Yellow fungus. Designating fungus on colours generates embarrassment. Mucormycosis has been called one of the "most feared infections in all ofinfectious diseases," and now it is surging as a COVID-19-associated infection throughout India and raising fire alarm bells around the globe. The contemporary internationally rampant of COVID-19 has affected a large number of patients to fungal pneumonias,Respiratory diseaseswhich carries a risk of developing triple threat of pandemic White, Yellow and Green fungal diseases. Aspergillosis, Mucormycosis and Candida are the main cause of invasive fungal infections. COVID-associated aspergillosis (CAPA) and (COVID-19-associated mucormycosis) CAMCR cases are well registered. “Black fungus is the crossing of COVID-19 and uncontrolled Diabetic mellitus in the pandemic. Physicians are suspicious about (COVID-19-associated mucormycosis) CAMCR especially if a rhino-orbitalsare notedin COVID-19 .DM (Diabetes Mellitus) patient with COVID-19 develop On the other hand Candidiasis, are not life threatening, and is common in ICU Covid-19 patients.


Coccidioides Immitis; Aspergillus fumigatus; Histoplasma capsulatum; Blastomyces dermatitidis; Cryptococcus neoformans, Candida Albicans, Pulmonary mycormycosis, Leukemia, Neutropenia, Gastrointestinal mucormycosis, Liposomal amphotericin B


[1] World Health Organization. Coronavirus Disease (COVID-19) pandemicAvailable from: Accessed 13 May 2020
[2] Lu R, Zhao X, Li J, Niu P, Yang B, Wu H. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 395(10224) ( 2020) 565–574.
[3] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 382(18) (2020) 1708–1720.
[4] Yang X., Yu Y., Xu J., Shu H., Xia J., Liu H. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet RespirMed. 2020
[5] He F., Deng Y., Li W. Coronavirus disease 2019 (COVID-19): what do we know? J Med Virol. 2020;14
[6] Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H. Clinical and immunologic features in severe and moderate Coronavirus disease 2019. J Clin Invest. 2020:137244
[7] Gorbalenya AE, Baker SC, Baric RS, et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 5(4) (2020) 536–544.
[8] Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. (2020).
[9] Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. J Infect. (2020).
[10] Beer, Karlyn D. MS, PhD1; Jackson, Brendan R. MD, MPH1; Chiller, Tom MD, MTMH1; Verweij, Paul E. MD, PhD2; Van de Veerdonk, Frank L. MD, PhD2; Wauters, Joost MD, PhD3 Does Pulmonary Aspergillosis Complicate Coronavirus Disease 2019?,Critical Care Explorations: 2(9) (2020) - p e0211
[11] Schwartz IS, Friedman DZP, Zapernick L, et al. High rates of influenza-associated invasive pulmonary aspergillosis may not be universal: A retrospective cohort study from Alberta, Canada. Clin Infect Dis. (2020).
[12] Ricotta EE, Lai YL, Babiker A, et al. Invasive candidiasis species distribution and trends, United States, 2009–2017. J Infect Dis. 2020.
[13] Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med.; 382 (2020) 1708- 172
[14] Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected With SARS-CoV-2 admitted to ICUs of the lombardy region, Italy. JAMA. 323 (2020) 1574- 1581
[15] Garcia-Vidal C, Sanjuan G, Moreno-Garcia E, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. ClinMicrobiol Infect. 2020.
[16] D H,Web desk,Covid-19: All you need to know about 'yellow fungus Yellow fungus, or mucor septicus, is a fungal infection that medical experts say generally does not occur in humans, but in lizards,MAY 25 2021, 13:28
[17] Ricardo Rabagliati , Nicolás Rodríguez, Carolina Núñez, Alvaro Huete, Sebastian Bravo, and Patricia Garcia,COVID-19–Associated Mold Infection in Critically Ill Patients, Chile, 27(5) (2021).
[18] Chander, Jagdish (2018). "26. Mucormycosis". Textbook of Medical Mycology (4th ed.). New Delhi: Jaypee Brothers Medical Publishers Ltd. 534–596.
[19] Yamin, Hasan S.; Alastal, Amro Y.; Bakri, Izzedin (January 2017). Pulmonary Mucormycosis Over 130 Years: A Case Report and Literature Review. Turkish Thoracic Journal. 18 (1): 1–5.
[20] Slavin, M.; Van Hal, S.; Sorrell, T.; Lee, A.; Marriott, D.; Daveson, K.; Kennedy, K.; Hajkowicz, K.; Halliday, C.; Athan, E.; et al. Invasive infections due to filamentous fungi other than Aspergillus: Epidemiology and determinants of mortality. Clin. Microbiol. Infect. 2015, 21, 490
[21] Ian Schwartz, ArunalokeChakrabarti (June 2, 2021). Black fungus' is creating a whole other health emergency for Covid-stricken India. The Guardian. Retrieved June 3, 2021.
[22] Hallen-Adams, H.E.; Suhr, M.J. Fungi in the healthy human gastrointestinal tract. Virulence, 8 (2017) 352–358.
[23] Rolling, T.; Hohl, T.M.; Zhai, B. Minority report: The intestinal mycobiota in systemic infections. Curr. Opin. Microbiol.56 (2020) 1–6
[24] Arastehfar, A.; Carvalho, A.; Van De Veerdonk, F.L.; Jenks, J.D.; Köhler, P.; Krause, R.; Cornely, O.A.; Perlin, D.S.; Lass-Flörl, C.; Hoenigl, M. COVID-19 Associated Pulmonary Aspergillosis (CAPA)—From Immunology to Treatment. J. Fungi, 6 (2020) 91
[25] Benedict K, Kobayashi M, Garg S, Chiller T, Jackson BR. Symptoms in blastomycosis, coccidioidomycosis, and histoplasmosis versus other respiratory illnesses in commercially insured adult outpatients, United States, 2016–2017external icon. Clin Infect Dis. 2020 Oct 16
[26] Shah AS, Heidari A, Civelli VF, Sharma R, Clark CS, Munoz AD, et al. The coincidence of 2 epidemics, coccidioidomycosis and SARS-CoV-2: a case reportexternal icon. J Investig Med High Impact Case Rep. 2020 Jun 4
[27] Bertolini M, Mutti MF, Barletta JA, et al. COVID-19 associated with AIDS-related disseminated histoplasmosis: a case reportexternalicon.Int J STD AIDS. 2020 Sep 9
[28] Yousef Shweihat, James Perry, III,1 and Darshana Shah, Isolated Candida infection of the lung Respir Med Case Rep. 2015; 16: 18–19.
[29] Liao, M.; Liu, Y.; Yuan, J.; Wen, Y.; Xu, G.; Zhao, J.; Cheng, L.; Li, J.; Wang, X.; Wang, F.; et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. Med., 26 (2020) 842–844.
[30] Zheng, M.; Gao, Y.; Wang, G.; Song, G.; Liu, S.; Sun, D.; Xu, Y.; Tian, Z. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell. Mol. Immunol. 17 (2020) 533–535.
[31] Giamarellos-Bourboulis, E.J.; Netea, M.G.; Rovina, N.; Akinosoglou, K.; Antoniadou, A.; Antonakos, N.; Damoraki, G.; Gkavogianni, T.; Adami, M.-E.; Katsaounou, P.; et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe, 27 (2020) 992–1000.
[32] Abad A, Fernández-Molina JV, Bikandi J, Ramírez A, Margareto J, Sendino J, et al. What makes Aspergillus fumigatus a successful pathogen? Genes and molecules involved in invasive aspergillosis. Rev IberoamMicol.27(4) ( 2010) 155-82.
[33] Lin J-S, Huang J-H, Hung L-Y, Wu S-Y, Wu-Hsieh BA. Distinct roles of complement receptor 3, Dectin-1, and sialic acids in murine macrophage interaction with Histoplasma yeast. J Leukoc Biol. 88(1) (2010) 95-106.
[34] Morton CO, Bouzani M, Loeffler J, Rogers TR. Direct interaction studies between Aspergillus fumigatus and human immune cells; what have we learned about pathogenicity and host immunity? Front Microbiol. 3 (2012) 413.
[35] Karki R, Man SM, Malireddi RKS, Gurung P, Vogel P, Lamkanfi M, et al. Concerted activation of the AIM2 and NLRP3 inflammasomes orchestrates host protection against Aspergillus infection. Cell Host Microbe. 2015;17:357-68. 11. Man SM, Karki R, Briard B, Burton A, Gingras S, Pelletier S, et al. Differential
roles of caspase-1 and caspase-In infection and inflammation. Sci Rep. 2017;7:45126.
[36] Viriyakosol S, Jimenez Model P, Gurney MA, Ashbaugh ME, Fierer J. Dectin-1 is required for resistance to coccidioidomycosis in mice. MBio. 2013;4:e00597-12.
[37] Meece JK, Anderson JL, Gruszka S, Sloss BL, Sullivan B, Reed KD. Variation in clinical phenotype of human infection among genetic groups of Blastomyces dermatitidis. J Infect Dis. 2013;207(5):814-22.
[38] Saccente M, Woods GL. Clinical and laboratory update on blastomycosis. ClinMicrobiol Rev. 23 (2010) 367- 81
[39] Viriyakosol S, Jimenez Model P, Gurney MA, Ashbaugh ME, Fierer J. Dectin-1 is required for resistance to coccidioidomycosis in mice. MBio. 2013;4:e00597-12.
[40] Pfeiffer CD, Fine JP, Safdar N.2006, Diagnosis of invasive aspergillosis using a GM assay.A metaanalysis.Clin.Inf.Dis.42:1417-1427
[41] Marr KA, Balaji SA et al. 2004.Detection of Galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillus.Variables that affect performance.J.inf.Dis 190:641-649
[42] Sandhya A.Kamath, Sidharth N Shah, Milland Y Nadkar.API Textbook of Medicine,11 th Ed, Vol2,2019
[43] Larone DH. Medically important fungi: a guide to identification. Washington DC: ASM Press, 2011.
[44] Hammond SP, Bialek R, Milner DA, Petschnigg EM, Baden LR, Marty FM. Molecular methods to improve diagnosis and identification of mucormycosis. J ClinMicrobiol 45 (2011) 2151–2153.
[45] Bialek R, Konrad F, Kern J et al. PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue. J ClinPathol 2005; 58: 1180–1184.
[46] David W.Denning,Chapter 212,Aspergillosis,Jamson,Fauci,Kasper,Hauser,Longo, Loscalzo, Harrison's principles of internal medicine,20 th Ed,Vol-1,Mc Grill Ed
[47] Eloise, M.Harman , Aspergillosis Treatment & Management, 2019,Drugs & Diseases > Pulmonology
[48] Jenks JD1, HoeniglM,Treatment of Aspergillosis,J Fungi (Basel). 2018 Sep; 4(3): 98.
[49] Pfaller M A, Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Future Research Priorities in Fungal Resistance | The Journal of Infectious Diseases | Oxford Academic, Am J Med, 2012
[50] Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F, et al. Recent exposure to caspofungin or fluconazole.influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients external icon Antimicrob Agents Chemother2011;55:532–8.
[51] Shah DN, Yau R, Lasco TM, Weston J, Salazar M, Palmer HR, et al. Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemiaexternalicon.Antimicrob Agents Chemother, 56 (2012) 3239–43.
[52] Ben-Ami R, Olshtain-Pops K, Krieger M, Oren I, Bishara J, Dan, M, et al. Antibiotic exposure as a risk factor forfluconazole-resistant Candida bloodstream infectionexternal icon. Antimicrob Agents Chemother,56 (2012) 2518–23.
[53] Ostrowsky B, Greenko J, Adams E, Quinn M, O’Brien B, ChaturvediV , et al. Candida auris isolates resistant to three classes of antifungal medications — New York, 2019. MMWR Morb Mortal Wkly Rep 2020;69:6–9.